FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Finch Therapeutics Group, Inc. [FNCH]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Smith Mark Burnham				-	I men inclupedates oroug, men [11011]							X Director	r	10% Owner		ner	
(Last) (First) (Middle)				3.	Date of Earliest Transaction (Month/Day/Year)							X Officer (below)	(give title		Other (specification)	pecify	
C/O FINCH THERAPEUTICS GROUP, INC.				0	03/18/2021						Chief Executive Officer						
200 INNER BELT ROAD, SUITE 400																	
					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable						
(Street)												Line	,	ed by One	Renorti	ina Person	
SOMER	VILLE M	IA	02143										_	ed by More		Ü	- 1
(City)	(5	state)	(Zip)										Person	,			
(City)	(3	siale)	(Ζιμ)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				ite	Execution Date,		Code (Instr.			Beneficia Owned Fe	s Formally (D) o		Direct I ndirect E tr. 4) (7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) c (D)	Price	Reported Transacti (Instr. 3 a	orted saction(s) tr. 3 and 4)		(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
				g., puts	s, cai				_								
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code	5. Numb Derivativ Securitic Acquire or Dispo of (D) (Ir 3, 4 and		vative irities (Month/Day/Ye irited (A) sposed (Instr.		Date	e of Securities		ies g e Security	8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Employee Stock Option (right to buy)	\$17	03/18/2021		A		595,402		(1)	03	3/17/2031	Common Stock	595,402	\$0.00	595,40	2	D	

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on March 18, 2022, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

Remarks:

/s/ Jason Minio, Attorney-in-

Fact

** Signature of Reporting Person Date

03/18/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.